CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., …Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. https://doi.org/10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More about CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma (2017)
Journal Article
Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Molecular Therapy - Nucleic Acids, 8(15 September 2017), 317-329. https://doi.org/10.1016/j.omtn.2017.07.001

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis, and most patients initially are or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9p21.3, whi... Read More about MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma.

EGFR and related therapeutic targets in malignant pleural mesothelioma (2016)
Thesis
Oguh, L. I. (2016). EGFR and related therapeutic targets in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4221787

Introduction Malignant pleural mesothelioma (MPM) is a rare but aggressive disease and the current first line treatment is associated with a survival rate of 40%. There is currently no second line therapy. This study aimed to explore the expression... Read More about EGFR and related therapeutic targets in malignant pleural mesothelioma.

Investigating the role of microRNA-31 as a modulator of chemosensitivity in malignant leural mesothelioma (2016)
Thesis
Moody, H. L. (2016). Investigating the role of microRNA-31 as a modulator of chemosensitivity in malignant leural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4219227

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis and the majority of patients are initially or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9... Read More about Investigating the role of microRNA-31 as a modulator of chemosensitivity in malignant leural mesothelioma.

Merkel cell carcinoma in East Yorkshire: A case series and literature review of current management (2015)
Journal Article
Jackson, P. C., Wallis, K., Allgar, V., Lind, M. J., & Stanley, P. R. (2015). Merkel cell carcinoma in East Yorkshire: A case series and literature review of current management. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 68(5), 667-672. https://doi.org/10.1016/j.bjps.2014.12.021

© 2015 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Introduction Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumour of the skin. The incidence is rising and it is associated with sun exposure and immunos... Read More about Merkel cell carcinoma in East Yorkshire: A case series and literature review of current management.

Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker (2014)
Journal Article
Garimella, V., Hussain, T., Agarwal, V., Radhakrishna, S., Fox, J. N., Kneeshaw, P. J., …Cawkwell, L. (2014). Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker. International journal of surgery, 12(8), 821-826. https://doi.org/10.1016/j.ijsu.2014.06.009

Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past. Aromatase inhibitors may be more beneficial than tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to retro... Read More about Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

Proteomic identification of putative biomarkers of radiotherapy resistance (2012)
Thesis
Scaife, L. (2012). Proteomic identification of putative biomarkers of radiotherapy resistance. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4214086

Background Currently, tumour response to radiotherapy cannot be predicted meaning that those patients with tumours resistant to the therapy endure the harmful side effects associated with ionising radiation in the absence of therapeutic gain. The ai... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance.

Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer (2012)
Thesis
ElFadl, D. (2012). Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4218629

Background: Breast cancer is an important health issue. The majority of patients present with early stage cancer and are therefore candidates for breast conserving surgery and radiotherapy. A proportion will suffer from local recurrence, which may b... Read More about Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer (2012)
Journal Article
Hodgkinson, V. C., Agarwal, V., ElFadl, D., Fox, J. N., McManus, P. L., Mahapatra, T. K., …Cawkwell, L. (2012). Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 75(9), 2745-2752. https://doi.org/10.1016/j.jprot.2012.03.049

Neoadjuvant chemotherapy is used to treat oestrogen receptor-positive breast cancer however chemo-resistance is a major obstacle in this molecular subtype. The ability to predict tumour response would allow chemotherapy administration to be directed... Read More about Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.